Tolerability of perampanel : a retrospective study at the department of psychiatry

Matsuyama, Taiki; Horinouchi, Toru; Nakamura, Yuichi; Ishikawa, Shuhei; Hashimoto, Naoki; Kusumi, Ichiro

Tolerability of perampanel : a retrospective study at the department of psychiatry

Matsuyama, Taiki; Horinouchi, Toru; Nakamura, Yuichi et al.

Epilepsy & behavior, 2024, 156, 109797

Permalink : https://hdl.handle.net/2115/95806

このアイテムのアクセス数:185件（2026-08-16 23:01 集計）

閲覧可能ファイル

ファイル	フォーマット	サイズ	閲覧回数	説明
HUSCAP_manuscript_revised_6	pdf	425 KB	113

論文情報

ファイル出力 EndNote Basic出力 Mendeley出力

アクセス権	open access
URI	https://hdl.handle.net/2115/95806
タイトル	Tolerability of perampanel : a retrospective study at the department of psychiatry
著者	Matsuyama, Taiki ; Horinouchi, Toru ; Nakamura, Yuichi ; Ishikawa, Shuhei ; Hashimoto, Naoki ; Kusumi, Ichiro
著者名 Matsuyama, Taiki
e-Rad_Researcher 80796029 著者名 Horinouchi, Toru
著者名 Nakamura, Yuichi
e-Rad_Researcher 30880091 著者名 Ishikawa, Shuhei
著者名 Hashimoto, Naoki
e-Rad_Researcher 30250426 著者名 Kusumi, Ichiro
言語	英語
キーワード	Perampanel
	Psychiatric adverse effects
	Psychiatric comorbidity
	Intellectual disability
	Anti-seizure medication
発行日	2024-07
出版者	Elsevier
収録物名	Epilepsy & behavior
巻(号)	156
ページ	109797
抄録	Purpose We aimed to identify factors that contribute to the discontinuation of perampanel. Methods We retrospectively analyzed patients with epilepsy at the Department of Psychiatry, Hokkaido University Hospital. We evaluated the factors contributing to perampanel discontinuation as primary outcomes using Cox proportional hazards regression. Then, we explored the components contributing to the primary outcomes using logistic regression analysis. Results A total of 118 patients were included, 44.9% of whom discontinued participation, 22.0% had intellectual disability, and 23.7% had a psychiatric disorder other than intellectual disability. Adverse effects occurred in 65% of the patients, 23.7% had psychiatric adverse effects (PAE), and 49.2% had common adverse effects (CAE). The effect of PER to suppress seizures was confirmed in 65.3% of them. Discontinuation was influenced by non-response (Hazard Ratio (HR) 6.70, 95% Confidence Interval (CI) 3.42–13.1), the occurrence of PAE (HR 3.68, 95% CI 1.89–7.16), CAE (HR 1.90, 95% CI 1.06–3.41), and comorbid psychiatric disorders (HR 2.35, 95% CI 1.21–4.59). Moreover, comorbid intellectual disability correlated with a low risk of PAE (OR 0.19, 95% CI 0.04–0.89). Conclusion The discontinuation of perampanel is influenced by poor efficacy and the occurrence of common/psychiatric adverse effects. The discontinuation of perampanel is influenced by poor efficacy and the occurrence of common/psychiatric adverse effects. Consideration of factors contributing to perampanel discontinuation may assist in determining the indication for perampanel treatment.
資源タイプ	学術雑誌論文
出版タイプ	Accepted Manuscript
権利情報	Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International
権利情報	© 2024. This manuscript version is made available under the CC-BY-NC-ND 4.0 license https://creativecommons.org/licenses/by-nc-nd/4.0/
PISSN	1525-5050
EISSN	1525-5069
関連情報 (isVersionOf)	出版社版DOI https://doi.org/10.1016/j.yebeh.2024.109797